{"id":"rituximab-cvp","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on B-cell lymphomas, leading to antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis. The CVP chemotherapy component provides additional cytotoxic activity against rapidly dividing lymphoma cells. This combination approach leverages both immunotherapy and conventional chemotherapy mechanisms.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, combined with CVP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to treat lymphoma.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:25.603Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma (in combination with CVP chemotherapy)"},{"name":"Diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT06045247","phase":"PHASE2","title":"Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-05","conditions":"Large B-cell Lymphoma","enrollment":40},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT06700798","phase":"PHASE2","title":"Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial","status":"RECRUITING","sponsor":"Fei Li","startDate":"2024-12-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":90},{"nctId":"NCT01476787","phase":"PHASE3","title":"Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-12-29","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT01303887","phase":"PHASE3","title":"A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2009-10","conditions":"Follicular Lymphoma","enrollment":680},{"nctId":"NCT02406092","phase":"PHASE3","title":"Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-13","conditions":"Non-Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT00115700","phase":"PHASE3","title":"Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2000-02","conditions":"Follicular Lymphoma","enrollment":150},{"nctId":"NCT01332968","phase":"PHASE3","title":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":1401},{"nctId":"NCT00384111","phase":"PHASE3","title":"Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2006-10","conditions":"Follicular Lymphoma, Lymphoma, Follicular","enrollment":26},{"nctId":"NCT01427114","phase":"PHASE2","title":"R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)","status":"COMPLETED","sponsor":"Konkuk University Medical Center","startDate":"2011-07-01","conditions":"Lymphoma","enrollment":33},{"nctId":"NCT01889069","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-31","conditions":"Lymphoma","enrollment":159},{"nctId":"NCT02162771","phase":"PHASE3","title":"To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan","status":"COMPLETED","sponsor":"Celltrion","startDate":"2014-07-14","conditions":"Lymphoma, Follicular","enrollment":140},{"nctId":"NCT01055496","phase":"PHASE1","title":"Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"Lymphoma, B-Cell","enrollment":103},{"nctId":"NCT00774202","phase":"PHASE2, PHASE3","title":"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-11","conditions":"Immune Thrombocytopenic Purpura","enrollment":17},{"nctId":"NCT01200758","phase":"PHASE3","title":"A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02-15","conditions":"Non-Hodgkin's Lymphoma","enrollment":410},{"nctId":"NCT00133991","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-07","conditions":"Leukemia, Lymphoma","enrollment":23},{"nctId":"NCT00161564","phase":"PHASE2","title":"A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2004-02","conditions":"Idiopathic Thrombocytopenic Purpura (ITP)","enrollment":""},{"nctId":"NCT03513601","phase":"PHASE4","title":"Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2017-07-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":20},{"nctId":"NCT00877006","phase":"PHASE3","title":"Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-04-30","conditions":"Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":447},{"nctId":"NCT01724021","phase":"PHASE3","title":"A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-12","conditions":"Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma","enrollment":743},{"nctId":"NCT00562965","phase":"PHASE3","title":"Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Lymphoma, Follicular","enrollment":29},{"nctId":"NCT00801281","phase":"PHASE3","title":"First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2007-02","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma","enrollment":250},{"nctId":"NCT00719472","phase":"PHASE3","title":"A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07","conditions":"Non-Hodgkin's Lymphoma","enrollment":451},{"nctId":"NCT03151044","phase":"PHASE3","title":"R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL","status":"UNKNOWN","sponsor":"FENG Ji-feng","startDate":"2016-07","conditions":"Diffuse Large B-cell Lymphoma","enrollment":408},{"nctId":"NCT01213095","phase":"PHASE2","title":"Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)","status":"COMPLETED","sponsor":"Dong-A University Hospital","startDate":"2010-09","conditions":"Lymphoma","enrollment":48},{"nctId":"NCT00842114","phase":"PHASE2","title":"Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)","status":"COMPLETED","sponsor":"Fundación Leucemia y Linfoma, Spain","startDate":"2006-02","conditions":"Non-Hodgkin's Lymphoma","enrollment":50},{"nctId":"NCT02461290","phase":"","title":"Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Follicular Lymphoma","enrollment":99},{"nctId":"NCT00971763","phase":"PHASE2","title":"Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2006-03","conditions":"Lymphoma","enrollment":62},{"nctId":"NCT00774826","phase":"PHASE3","title":"Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2005-12","conditions":"Follicular Lymphoma","enrollment":534},{"nctId":"NCT00193440","phase":"PHASE2","title":"Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2002-04","conditions":"Non-Hodgkins Lymphoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rituximab - CVP","genericName":"Rituximab - CVP","companyName":"The Lymphoma Academic Research Organisation","companyId":"the-lymphoma-academic-research-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is used in combination with Cyclophosphamide and Prednisone (CVP) to treat various types of B-cell lymphomas, including Large B-cell Lymphoma, Follicular Lymphoma, and Non-Hodgkin's Lymphoma. Rituximab works by binding to the B-lymphocyte antigen CD20, a protein found on the surface of B cells.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}